BIOADAPTIVES, INC. (BDPT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 6K 12K 18K Q3 '21: 5.3K Q4 '21: 3.9K Q1 '22: 5.5K Q2 '22: 4.3K Q3 '22: 3.3K Q4 '22: 4K Q1 '23: 3.4K Q2 '23: 2.3K Q3 '23: 15.6K Q4 '23: 7.2K Q1 '24: 12K Q2 '24: 675 Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 3.2K Q3 '25: 4.6K Q4 '25: 10.4K Q1 '26: 5.5K Q2 '26: 5K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 3K 6K 9K Q3 '21: 3.1K Q4 '21: 1.1K Q1 '22: 1.9K Q2 '22: 2.2K Q3 '22: 2K Q4 '22: 1K Q1 '23: 2K Q2 '23: 1.5K Q3 '23: 4.7K Q4 '23: 2.7K Q1 '24: 3.6K Q2 '24: 429 Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 1.1K Q3 '25: 3.9K Q4 '25: 7.6K Q1 '26: 4.1K Q2 '26: 4.2K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-450K -300K -150K 0 150K 300K 450K Q2 '15: -109.4K Q3 '15: -40.1K Q4 '15: -48.5K Q1 '16: -80.9K Q2 '16: -33.2K Q3 '16: -26.3K Q1 '23: -19K Q2 '23: -55.9K Q3 '23: -92.2K Q4 '23: -61.8K Q1 '24: -49.8K Q2 '24: -93K Q3 '24: -121.9K Q4 '24: -337.3K Q1 '25: -249.1K Q2 '25: -279.2K Q3 '25: -265.7K Q4 '25: -248.1K Q1 '26: -198.2K Q2 '26: -197.2K Q3 '15 Q2 '16 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-900K -600K -300K 0 300K 600K 900K Q3 '21: -34.5K Q4 '21: -214.3K Q1 '22: -367.1K Q2 '22: -223.8K Q3 '22: -276.3K Q4 '22: -28.3K Q1 '23: -287.2K Q2 '23: -143.9K Q3 '23: -13.1K Q4 '23: -268.3K Q1 '24: -306.7K Q2 '24: -183K Q3 '24: -37.6K Q4 '24: -371.8K Q1 '25: -197.1K Q2 '25: -157.9K Q3 '25: -379.5K Q4 '25: -823.3K Q1 '26: -111.1K Q2 '26: 150.1K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 4K 8K 12K Q3 '21: 2.2K Q4 '21: 2.7K Q1 '22: 3.6K Q2 '22: 2.2K Q3 '22: 1.3K Q4 '22: 3K Q1 '23: 1.4K Q2 '23: 849 Q3 '23: 11K Q4 '23: 4.5K Q1 '24: 8.4K Q2 '24: 246 Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 2.2K Q3 '25: 781 Q4 '25: 2.8K Q1 '26: 1.4K Q2 '26: 748 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-180K -120K -60K 0 60K 120K 180K Q3 '21: -33.2K Q4 '21: -35.4K Q1 '22: -61.2K Q2 '22: -77.1K Q3 '22: -61.5K Q4 '22: -27.5K Q1 '23: -19.5K Q2 '23: -56.9K Q3 '23: -56.1K Q4 '23: -91.3K Q1 '24: -41.2K Q2 '24: -51.5K Q3 '24: -56.3K Q4 '24: -100.5K Q1 '25: -97.9K Q2 '25: -111K Q3 '25: -151.3K Q4 '25: -155.8K Q1 '26: -84.8K Q2 '26: -44.4K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-180K -120K -60K 0 60K 120K 180K Q3 '14: 10.5K Q4 '14: -45.7K Q3 '24: -56.3K Q4 '24: -100.5K Q3 '25: -151.3K Q4 '25: -155.8K Q3 '14 Q4 '14 Q3 '24 Q4 '24 Q3 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 250M 500M 750M Q3 '13: 10M Q1 '14: 12.1M Q2 '14: 12.6M Q3 '14: 12.6M Q1 '19: 22.6M Q1 '20: 18.9M Q3 '23: 730M Q1 '24: 7.7M Q2 '24: 3M Q3 '24: 8.2M Q1 '25: 9M Q2 '25: 9.5M Q3 '25: 10.2M Q1 '26: 12M Q2 '26: 281.2M Q3 '13 Q2 '14 Q1 '19 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.21 -0.14 -0.07 0.00 0.07 0.14 0.21 Q3 '16: -0.02 Q4 '18: -0.08 Q1 '19: -0.08 Q2 '19: -0.07 Q3 '19: -0.03 Q4 '19: -0.01 Q1 '20: -0.02 Q2 '20: -0.03 Q3 '20: -0.03 Q4 '20: -0.04 Q1 '21: -0.05 Q2 '24: -0.10 Q3 '24: -0.10 Q4 '24: -0.09 Q1 '25: -0.07 Q2 '25: -0.15 Q3 '25: -0.19 Q4 '25: -0.15 Q1 '26: -0.14 Q2 '26: -0.12 Q4 '18 Q3 '19 Q2 '20 Q1 '21 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.